BridgeBio Pharma Inc. (NASDAQ: BBIO) is 77.69% higher on its value in year-to-date trading and has touched a low of $5.74 and a high of $19.94 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BBIO stock was last observed hovering at around $13.29 in the last trading session, with the day’s gains setting it 0.25% off its average median price target of $29.00 for the next 12 months. It is also 66.15% off the consensus price target high of $40.00 offered by 11 analysts, but current levels are 24.78% higher than the price target low of $18.00 for the same period.
Currently trading at $13.54, the stock is -2.90% and -7.58% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.12 million and changing 1.88% at the moment leaves the stock 18.84% off its SMA200. BBIO registered 101.49% gain for a year compared to 6-month gain of 58.73%. The firm has a 50-day simple moving average (SMA 50) of $43.90 and a 200-day simple moving average (SMA200) of -$10.06.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The stock witnessed a -5.25% loss in the last 1 month and extending the period to 3 months gives it a 16.22%, and is -3.15% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.57% over the week and 6.02% over the month.
BridgeBio Pharma Inc. (BBIO) has around 392 employees, a market worth around $2.21B and $77.80M in sales. Distance from 52-week low is 135.89% and -32.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-113.10%).
BridgeBio Pharma Inc. (BBIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for BridgeBio Pharma Inc. (BBIO) is a “Buy”. 11 analysts offering their recommendations for the stock have an average rating of 1.60, where 0 rate it as a Hold and 1 think it is a “Overweight”. 10 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
BridgeBio Pharma Inc. is expected to release its quarterly report on 08/03/2023.The EPS is expected to grow by 16.30% this year
BridgeBio Pharma Inc. (BBIO) Top Institutional Holders
The shares outstanding are 152.65M, and float is at 107.05M with Short Float at 12.42%.
BridgeBio Pharma Inc. (BBIO) Insider Activity
A total of 20 insider transactions have happened at BridgeBio Pharma Inc. (BBIO) in the last six months, with sales accounting for 16 and purchases happening 4 times. The most recent transaction is an insider sale by Kumar Neil, the company’s CEO and President. SEC filings show that Kumar Neil sold 51,552 shares of the company’s common stock on May 17 at a price of $14.01 per share for a total of $0.72 million. Following the sale, the insider now owns 4.81 million shares.
BridgeBio Pharma Inc. disclosed in a document filed with the SEC on May 17 that STEPHENSON BRIAN C (Secretary, Treasurer & CFO) sold a total of 24,424 shares of the company’s common stock. The trade occurred on May 17 and was made at $14.01 per share for $0.34 million. Following the transaction, the insider now directly holds 36408.0 shares of the BBIO stock.
Still, SEC filings show that on May 03, Kumar Neil (CEO and President) disposed off 120,000 shares at an average price of $14.18 for $1.7 million. The insider now directly holds 1,012,722 shares of BridgeBio Pharma Inc. (BBIO).
